Detalhe da pesquisa
1.
Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma.
Blood
; 142(10): 878-886, 2023 09 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37319435
2.
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.
Blood
; 137(5): 600-609, 2021 02 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33538797
3.
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study.
Am J Hematol
; 98(3): 449-463, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36594167
4.
Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing.
Blood
; 136(5): 572-584, 2020 07 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-32160292
5.
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Lancet Oncol
; 22(4): 512-524, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33721562
6.
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087.
Blood
; 134(14): 1144-1153, 2019 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31409671
7.
Loss of HER2-positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes.
J Surg Oncol
; 124(8): 1224-1234, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34416025
8.
Do Mountain Bikers Know When They Have Had a Concussion and, Do They Know to Stop Riding?
Clin J Sport Med
; 31(6): e414-e419, 2021 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31895715
9.
Time to surgery following neoadjuvant chemotherapy for breast cancer impacts residual cancer burden, recurrence, and survival.
J Surg Oncol
; 122(8): 1761-1769, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33125715
10.
Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements.
Blood
; 129(3): 280-288, 2017 01 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-27821509
11.
Presidential Address: A Long Time Ago in the Future.
Ann Surg Oncol
; 30(10): 5947-5950, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37548835
12.
Ethical Considerations of Medical Photography in the Management of Breast Disease.
Ann Surg Oncol
; 25(10): 2801-2806, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-29978370
13.
Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL.
Blood
; 127(18): 2182-8, 2016 05 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26834242
14.
Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.
Blood
; 128(2): 185-94, 2016 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-27166360
15.
Disruption of direct 3D telomere-TRF2 interaction through two molecularly disparate mechanisms is a hallmark of primary Hodgkin and Reed-Sternberg cells.
Lab Invest
; 97(7): 772-781, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28436953
16.
Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy.
N Engl J Med
; 380(24): 2375-2376, 2019 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31189042
17.
An RCOR1 loss-associated gene expression signature identifies a prognostically significant DLBCL subgroup.
Blood
; 125(6): 959-66, 2015 Feb 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-25395426
18.
MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.
Nature
; 471(7338): 377-81, 2011 Mar 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-21368758
19.
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.
Nature
; 476(7360): 298-303, 2011 Jul 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-21796119
20.
Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study.
PLoS Med
; 13(12): e1002197, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27959929